Podcasts about pharmavoice

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Raman Sehgal, Founder & Global President at ramarketing & Host of Molecule to Market. For this milestone episode, your host is Molecule to Market's first guest from back in 2020, JoyL Silva, Customer Engagement Lead for the US Primary Care portfolio at Pfizer, who discusses the pharmaceutical and biotechnology supply chain with Raman Sehgal covering: Raman reflects on the podcast's evolution, from its inception during COVID-19 to becoming a globally recognized platform They discuss key trends in the pharma outsourcing sector and the impact of guests who have contributed to the podcast's success Raman shares highlights from his career, including the growth of his companies, ramarketing and Lead Candidate, and his private equity ventures Insights into balancing work and family life, with advice on being present and managing priorities A desert island question where Raman chooses which podcast guests he'd bring along, plus behind-the-scenes stories of challenges and humorous incidents JoyL Silva is the Customer Engagement Lead for Pfizer's US Primary Care portfolio, overseeing sales and account management across therapeutic areas such as Migraine, Cardiovascular, Anti-virals, and Vaccines. She leads high-performing teams that drive a $20B portfolio through agile methodologies and talent development. With over 20 years at Pfizer, JoyL has excelled in commercial leadership, business transformations, and operational expertise, delivering impactful results across multiple roles, including VP for Hematology and Biosimilars, General Manager of Pfizer CentreOne, and US/Global Commercial Lead for PAXLOVID, where she spearheaded global strategies and partnerships for Pfizer's COVID-19 antiviral therapeutic. JoyL frequently speaks at industry forums and contributes her expertise to various publications and professional boards, including the Pharma & Biopharma Outsourcing Association. Her accolades include being named to the Medicine Maker Power List and PharmaVOICE 100 Most Inspiring People in the Life Sciences Industry, as well as receiving awards such as the Scrip Best Partnership Alliance Award and Putnam Media Top 20 Influential Women in Manufacturing. Her career reflects a strong commitment to driving innovation and fostering leadership in the life sciences sector. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!    Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

On so many issues, Congress has not been willing or able to act. But when faced with horrifying stories of death and mismanagement, Congress finally passed legislation to reform the US organ transplant system. They did so because people like Donna Cryer, a transplant recipient and patient advocate, demanded a better system for Americans who need lifesaving organ transplants. Now, as the new law moves into implementation, the work continues. In this episode, Donna and I discuss:The new legislation that is breaking up the deadly organ transplant monopolyHow ignoring the expertise and insights of patients dooms us to slow progress making healthcare safer and better Her advice for young people: “take your shot”Donna says we all need to start listening more closely to patients with lived experience:“I often think if you... had many people with great deals of experience and intelligence who were highly motivated to help you achieve your goal. Why would you not want to use them? Why would you not want to partner with them? Why would you work really, really hard to keep them away from solving the problem? And that's how people treat patients and patient advocates.”Relevant LinksDonna Cryer's testimony to the Senate Finance Committee on organ transplant system failures (just past the 48:00 mark)Summary of the new law to break up the organ transplantation monopolyMore about the Global Liver InstituteSee more details about the Advanced Advocacy Academy Donna's organization launchedVisit UNOS' websiteAbout Our GuestDonna R. Cryer, JD is the Founder and former Chief Executive Officer of Global Liver Institute, the only patient-driven liver health nonprofit operating across the US, EU, and UK. GLI convenes the NASH, Liver Cancer and Pediatric and Rare Liver Disease Councils, as well as the Liver Action Network, collectively more than 200 organizations.Mrs. Cryer has channeled her personal experience as a patient with inflammatory bowel disease and a 29-year liver transplant recipient into professional advocacy across a career in law, policy, consulting, public relations, clinical trial recruitment, and nonprofit management. At GLI, Mrs. Cryer has raised more than $10 million for liver health initiatives. She is a frequent speaker on the topic of patient-centeredness and patient engagement in healthcare transformation and created a unique model for advocacy that mobilizes patients, influences policy, and coalesces clinicians to improve patient outcomes.Mrs. Cryer serves on the Boards of Directors for the Council of Medical Specialty Societies, Sibley Memorial Hospital/Johns Hopkins Medicine, the Innovation and Value Initiative (IVI), and the Clinical Trials Transformation Initiative. She was the first patient to serve on the ABIM Gastroenterology Specialty Board, was one of the founding members of the AASLD Patient Advisory Committee and is the Community Representative on the AASLD NASH Task Force. She has been named one of the Top Blacks in Healthcare by the Milken Institute at GW School of Public Health and BlackDoctors.org, one of the Top 10 Patients Who Make An Impact by Health 2.0 and one of PharmaVoice's 100 Most...

In our first episode recorded live in front of an audience, we're with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering

Join host Leanne Woehlke and clinical research professional, Suzanne Kincaid, for a compelling conversation about the unseen demands of family caregiving. With candor and humor, Suzanne shares her journey managing the healthcare of multiple elderly family members, discussing the hurdles of medication management, doctor visits, and technology support. This episode dives deep into the practical and emotional sides of caregiving, exploring why self-care is essential yet often overlooked, and how systemic changes could ease the load on caregivers everywhere. For anyone supporting a loved one through aging or illness, this conversation offers insights, resources, and a reminder that you're not alone. Suzanne Kincaid, CCRA, ACRP-PM, FACRP Owner and Independent Consultant, Responsibility Research Suzanne has over 25 years of clinical research experience. She has conducted clinical trials from every aspect, from study coordinator to global project manager. She was the Study Delivery Program Leader of AstraZeneca's Oncology Phase I Team, Director of Operations for Sarah Cannon's Phase I Drug Development Unit, and Chief Operating Officer of Aperio Clinical Outcomes.   Suzanne's clinical research passions include process improvement, project management, training clinical research professionals, cultivating high performing teams, and Risk Based Quality Management.   Suzanne is actively involved in the Association of Clinical Research Professionals (ACRP), serving on the board of the Greater Nashville Chapter since 2011, and is currently Chair of the ACRP Fellows Advisory Panel.  In 2020, Suzanne was honored as one of the PharmaVoice 100 Most Inspiring People in Life Sciences. To connect with Suzanne on Linked In: https://www.linkedin.com/in/responsibilityresearch/

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Bayer has developed a successful audience targeting strategy that drives meaningful engagement, with Crossix audience segments optimizing campaigns and aligning messaging more closely with the patient journey. This precision targeting has proven effective in reaching the most qualified audience and increasing engagement.Philips issued a fix for ventilator problems linked to injuries and deaths, Siemens Healthineers received FDA approval for a 3D mammography system, and Synchron's brain-computer interface technology met safety goals. Additionally, the wearables market is expected to see growth, while the FDA missed a target date for releasing rules on pulse oximeters. Medtech Dive provides insights on medical technology trends and top conferences in 2025.A private equity firm, TPG, is set to acquire a majority stake in e-prescribing giant Surescripts. HCA's Mission Hospital in North Carolina faces challenges after Hurricane Helene, while UHS has been forced to pay significant damages related to child sexual abuse allegations. Efforts to combat burnout among healthcare workers are highlighted, along with sponsored content on safeguarding healthcare against cybercrime.Eli Lilly is investing $4.5 billion in a new manufacturing and research center in Indiana, while Amgen faces a class action lawsuit and Johnson & Johnson invests $2 billion in a North Carolina facility. Bayer, J&J, and Pfizer are collectively laying off nearly 500 employees, with new developments in cFDNA methylation assays and royalty financing for biopharma companies. ImmunityBio is also undergoing layoffs in California.Roche is facing an $8 billion sales gap due to biosimilar competition, prompting investments in new blockbuster drugs. Kailera Therapeutics has secured funding for obesity drugs, and the cell and gene therapy industry is experiencing rapid growth. Pharmavoice covers these topics and more in their daily newsletter.2seventy Bio is close to reaching cash flow breakeven, attributing their survival to transparency and a committed staff. Pfizer's withdrawal of sickle cell therapy Oxbryta has raised questions among investors. Royalty financing has become crucial for biopharma companies as traditional fundraising methods falter. Lilly's drug pricing practices are under scrutiny compared to Novo Nordisk. Various updates on investments, layoffs, and legal actions can be found on Biospace's website.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Roche's investment in startup Regor Therapeutics for a new breast cancer drug, worth $850 million, shows their commitment to innovative research. Prime's focus on gene editing research and partnership with Bristol Myers signifies the evolving landscape of biopharma collaborations. Aktis raising $175 million for radiopharma drug development, with support from investors like Bristol Myers, Eli Lilly, and Merck & Co., highlights the growing interest in this area. Bristol Myers' plans to sell a groundbreaking schizophrenia drug face potential challenges due to insurance barriers, impacting patient access. The newsletter covers blood-based biomarkers for Alzheimer's, company updates, and upcoming industry events, providing valuable insights into biopharma trends.Roche's acquisition of a CDK inhibitor from Regor for $850 million bolsters their breast cancer portfolio, as announced during Roche's pharma day presentation. J&J's positive Phase III results for Carvykti and Darzalex Faspro in multiple myeloma trials, along with Novartis' successful Lutathera radiopharma therapy for difficult-to-treat brain tumors, demonstrate significant advancements in cancer treatment. The FDA rejection of Lykos Therapeutics' PTSD therapy underscores the challenges in developing psychiatric disease therapies. WBL's new cfdna methylation assay aims to improve data quality in cfdna sequencing, enhancing research capabilities. Potential risks to women's health research and recent layoffs at companies like Inventprise raise concerns in the industry. Stay updated on upcoming events and job opportunities in the pharmaceutical sector.The phase 3 trial failure of Bristol Myers Squibb and 2seventy Bio's CAR-T cell therapy, Abecma, due to low enrollment emphasizes the importance of patient participation in clinical trials. The shift towards off-the-shelf CAR-T cell therapy approval by the FDA in January marks a significant milestone for drug developers like Atara Biosciences. Bristol Myers Squibb's new schizophrenia drug, Cobenfy, and the growing role of gene therapies in pharmaceutical manufacturing operations reflect the ongoing advancements in biopharma. Pharmavoice continues to deliver essential insights and perspectives in the life sciences industry.Stay informed with Pharma and Biotech daily for all the latest updates in the world of pharmaceuticals and biotechnology.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Private biotech funding is on the rise, with venture firms investing in cell therapy developments in cancer care. Century has acquired Clade Therapeutics and raised $60 million through a private placement led by Bain Capital to expand its cell therapy technology. In the first quarter of 2024, twenty-six drugmakers raised over $100 million each. The FDA has approved CAR-T therapies from J&J and Bristol Myers for earlier use in myeloma treatment. The industry is also closely watching drug pricing negotiations, as Medicare gains the authority to negotiate drug prices, which has been fiercely opposed by the industry in the past. Overall, the biopharma sector is seeing significant investment and advancements in cell and gene therapies, with a focus on improving treatment options for patients.Cell therapy is gaining traction in the market for cancer treatment, with advancements in technology supporting the complex process of extracting immune cells, engineering them, and reinfusing them back into patients. While uptake has been limited, the impact of cell therapy in cancer care is growing. Biotechs are working on expanding the use of CAR-T cell therapies for multiple myeloma and exploring the potential of cell therapy in autoimmune diseases like lupus. The future of cell therapies looks promising, with new developments on the horizon.On April 11, Vertex announced plans to acquire kidney disease drugmaker Alpine for $4.9 billion, marking its largest acquisition ever. Meanwhile, Century purchased startup Clade Therapeutics and raised $60 million in funding to expand its cell therapy capabilities. The biotech M&A trend is on the rise, with Vertex's deal being the largest in the industry so far this year. Additionally, J&J and Rallybio are partnering to develop a preventive therapy for a rare fetal condition. Regeneron is facing a lawsuit from the US government, alleging false price reporting on its blockbuster eye drug Eylea.The FDA has expanded its import ban on Chinese manufacturer Jiangsu Shenli Medical Production to include all plastic syringes due to quality system failures. Steris is selling its dental segment for $787.5 million to focus on healthcare, pharma, and medtech markets. Philips is restricted from selling respiratory machines in the US under a consent decree, with export restrictions in place to ensure timely device remediation for US patients.The text discusses the surge in mergers and acquisitions (M&A) within the pharmaceutical technology sector, highlighting the impact on the industry. It also explores the use of artificial intelligence (AI) in the pharma industry beyond drug discovery. The Pharmavoice 100 list features professionals making an impact in the industry, providing a platform for networking and recognition. It mentions eClinical Solutions CEO Raj Indupuri's perspective on being part of the list and the benefits it brings.Overall, significant developments are happening in biopharma industry ranging from funding to technological advancements and regulatory challenges. Stay tuned for more updates on Pharma and Biotech daily podcast.

Diagnostics in Life Sciences is the Key to Healthcare w/ Mara Aspinall of Illumina Ventures  AZ TRT S05 EP12 (227) 3-24-2024    What We Learned This Week Diagnostics is the key to healthcare, identifying medical issues and designing the right treatment for the patient Five Levels of Diagnostics – Screening, Diagnosis, Prognosis, Interacting, & Monitoring Illumina Ventures is a life sciences venture capital firm with 35 companies in their portfolio Their investment companies deal in genomics, cancer testing, telehealth, at home testing & more Future of Biotech will be impacted by both AI and Nanotech     Guest: Mara G. Aspinall, Partner, Illumina Ventures  https://www.illuminaventures.com/ President and CEO, Health Catalysts Group Board Member of AZ Bio - https://www.azbio.org/   Mara Aspinall is a healthcare industry leader and pioneer with a commitment to civic involvement.     She is a Partner at Illumina Ventures, an independent, global healthcare venture capital firm focused on genomics and precision health investing including diagnostics and therapeutic products. Aspinall has deep roots in venture investing, having co-founded BlueStone Venture Partners in 2017. BlueStone has a strong portfolio of diagnostic, medical device, and digital health companies in the U.S. Southwest. Throughout her career, Aspinall has spearheaded initiatives to educate payers and policymakers on genomics and personalized medicine. She publishes the popular Sensitive and Specific: The Testing Newsletter and the annual Diagnostics Year in Review. This commitment to expanding knowledge inspired Aspinall to create and co-found the Biomedical Diagnostics master's degree program at Arizona State University, the only program dedicated exclusively to diagnostics, genetics, and genomics. Previously, Aspinall was President and CEO of Ventana Medical Systems, a billion-dollar division of TheRoche Group, (now Roche Tissue Diagnostics), a worldwide leader in the development and commercialization of tissue-based cancer diagnostics, where she led more than two dozen major instrument and assay launches and helped position the company as a global leader in companion diagnostics. Aspinall spent 13 years at Genzyme Corporation, where she served as President of Genzyme Genetics and Genzyme Pharmaceuticals. Aspinall transformed the business from a small, specialized player to one of the top five laboratories in the U.S. while setting the industry standard for quality testing. The business was sold to LabCorp for $1 billion in 2010. Aspinall also served as Founder and CEO of On-Q-ity, a start-up diagnostic company dedicated to circulating tumor cells. During the pandemic, Aspinall emerged as a national authority on COVID testing, serving as the principal investigator at Arizona State University on grants from The Rockefeller Foundation, creating TestingCommons.com and EvidenceCommons.com – internationally recognized interactive databases on COVID diagnostics and related research and clinical applications. Aspinall was named Arizona Biosciences Leader of the Year by the Arizona Bioindustry Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine. Aspinall has extensive board experience. She has served on multiple public and private company boards in leadership roles over the last ten years. She is currently Chair of the Board of OraSure (OSUR) and Chair of the Nominating & Governance Committee of Castle Biosciences (CSTL). She also serves on the board of BlueCross BlueShield of Arizona. She holds an MBA from Harvard Business School, a BA in International Relations from Tufts University, and is certified in Cybersecurity Oversight from Carnegie Mellon/NACD.     Notes:   Seg 1 All of life sciences and biotech is healthcare. Diagnostics is the central organizing portion in healthcare, and consists of testing if needed. There are five (5) levels to diagnostics. Level One is Screening – where a patient may or may not be sick, check the health status, and also could be regular check ups for something pre-diagnosed.  Level Two is the Diagnosis - where tests are taken and then you see the results of the test. Level Three is the Prognosis – what symptoms does the patient have, and where you  need to go from here, what will happen with these symptoms. Level Four is a newer part called Interacting - This is where you can do personalized medicine and what's called theranostics or drug treatment. You combine drugs with the treatment. You have to analyze what type of drug is needed. What someone's body is like, how they metabolize drugs. What dose central levels are needed. People's reactions to drugs is not just body size or weight as suggested previously, but could be very much based on the genes. Level Five also new is called Monitoring - If disease treatment is over how do you monitor over the long term. What test do you take to confirm that there's been no return of the disease. Examples would be an MRD test which stands for a minimal residue disease.  You also may be doing things like CT scans or x-ray scans in the past, but sometimes these do not detect disease properly. Some cancers could be very small and you need a blood test. People may check in through cycles of a disease treatment also.   Seg 2 Regarding monitoring and Level Five using cancer as an example. People may go through 6 rounds of chemotherapy treatment. The doctor should monitor by round 3 and check is the tumor reduced or how is the chemo working.  Do you want to have benchmarks to see if you're reaching the health goals and if the medicine is effective. Future treatment might be biopsy of a tumor and testing glass to see what drug may work on it.  Revisiting Level Four in personalized medicine you may see in the future Chino metric analysis. Check the risk level for certain diseases so you can have a preemptive process to prevent potential predisposed diseases. This is level A. Level B would be when diagnosed with a disease, you check the tumor, mutations and genes checking both the DNA and RNA. Mara is on the board of AZ Bio (.org). The goal of AZ Bio is bringing educated people about biotech together to affect the state, the universities, and companies. Move research along with the responsibility to patients in the medical field. Mara is involved in venture capital which is critical, because it funds entrepreneurs in good companies to research and create Biotech product processes and products. There are other levels of investment, which typically start with friends and angel investing then move on to venture capital, and then private equity for really big rounds.  She was the founder of Blue Stone and they invested in Southwest companies.  In the fall of 2023 she became a partner at Illumina Ventures. They deal with 35 different companies. They've invested in all levels, biotech and genomics. You're looking for a VC to be specialized and knowledgeable about an industry so they can help the business grow provide it with money and add expertise.   Seg 3 Mara and Illumina Ventures recently put out a report - Diagnostics Year in Review. This report covers how did the industry is doing, what stocks earn money, what IPOs there were, financials, clinical, innovation, and mergers and acquisitions.   How does venture-capital work? Typically you have individual funds one through five. You raise money from investors and invest in new emerging companies. Companies may be doing research, drug development, or working other areas of life sciences.   Examples of companies in their portfolio: Delphi deals in cancer, diagnosis test and early screening for cancer and detection test. Level one screen checking for lung cancer and what early symptoms there are. Biopsy can be dangerous so you need other tests. Let's Get Checked - a telehealth online company that brings testing to the patient either at home or in an urgent care or ER. This is faster and easier. Examples of test are Covid test and STD test. Serimmune human immunity research company Genome Medical a genetic counseling company, working with patients to discuss what diseases they may be predisposed to, and ways to not pass it to the   Seg 4 Future of Biotech We saw with the pandemic, the rise of telemedicine with faster online diagnosis. We will also see in the future that AI changes drug development and reading tests The creation of better and faster equipment. The rise of nanotech, and early detection of diseases with blood samples - for example, at home blood draw.     Check out the Best of Biotech Show: Best of Biotech from AZ Bio & Life Sciences to Jellatech - BRT S04 EP26 (189) 7-2-2023   What We Learned This Week: AZ Bio mission to improve life sciences, & make AZ a Top 10 Bioscience state Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus Collagen 2.0 – Innovation to Gelatin & gummies   Full Show: HERE     AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023   Tech Topic: https://brt-show.libsyn.com/category/Tech-Startup-VC-Cybersecurity-Energy-Science  Best of Tech: https://brt-show.libsyn.com/size/5/?search=best+of+tech     ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.  

In this episode of Pharma and Biotech Daily, we cover a range of significant developments in the pharmaceutical and biotech industries. Sanofi has startled investors with a lowered profit outlook, while Eli Lilly and Merck report positive FDA approvals and sales growth. We also spotlight this year's Pharmavoice 100 honorees, featuring insights from industry leaders. In gene therapy news, various companies have received FDA approvals, released promising trial results, or announced significant mergers and funding rounds. Lastly, we discuss the challenges faced by the healthcare industry, including strained household budgets due to healthcare prices, and we provide updates on Takeda's financial struggles and recent successes in Alzheimer's disease trials.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.In our first news, we have a summary of an on-demand webinar that discusses how real-world data (RWD) can be leveraged in rare disease research. The use of RWD in clinical trials and drug development for rare diseases is explored by experts from Pfizer and Clarivate. They highlight the importance of RWD in narrowing the gap of knowledge surrounding rare diseases and how it can enhance clinical trials and improve drug development processes. Challenges associated with harnessing RWD effectively are also addressed, along with best practices for overcoming these obstacles. The goal is to optimize rare disease research by leveraging RWD and improving drug development efficiency.Moving on to our next news, we have a promotion for an on-demand webinar titled "High-Throughput Process & Analytical Platforms to Accelerate Gene Therapy Scale-Up." This webinar discusses various topics related to gene therapy scale-up and how innovative platforms can revolutionize the process. Some key points covered include serotype agnostic analytics for AAV manufacturing, challenges in scaling up to larger bioreactors, using an advanced platform with a reduced number of plasmids, and Resilience and Lacerta's innovations. Experts in the field share their insights, and interested individuals can connect with the Resilience team for support in gene therapy process and analytical development work.In regulatory news, the FDA has placed a partial clinical hold on two studies of Innate Pharma's investigational therapy lacutamab following a patient death from the rare blood disease hemophagocytic lymphohistiocytosis. Innate Pharma is working closely with the FDA to address the agency's concerns and provide the necessary data. In other news, an FDA advisory committee has backed the use of US WorldMeds' investigational drug for high-risk neuroblastoma, despite the lack of a randomized controlled trial. This decision could set a precedent for future drug approvals without randomized controlled trial data. Japan-based pharma company Kyowa Kirin is also acquiring Orchard Therapeutics pending regulatory approvals, and Johnson & Johnson's spravato has shown promising results in a phase III head-to-head study.Shifting gears to marketing and advertising, we discuss the importance of connected TV for marketers and how the Hollywood shutdown could disrupt the ad market. Disney's innovative holiday marketing strategies are highlighted, along with Olaplex's unique approach to addressing dupe culture on TikTok. Three Olives Vodka is mentioned for using AI to plan the perfect party, and Meta (formerly known as Facebook) is expanding access to its generative AI tools. Target has launched an immersive toy experience for online shoppers, allowing them to explore a virtual room of products.In the rare disease space, we delve into regulatory challenges related to the use of biomarkers to measure efficacy. The FDA recently approved Novo Nordisk's drug rivfloza for patients with primary hyperoxaluria, but there are concerns about shortcomings in regulatory policies when it comes to biomarkers for rare diseases. Leaders in the pharmaceutical industry who are skilled at translating scientific research into products that regulators see value in are recognized on this year's Pharmavoice 100 list.Lastly, we address the challenges faced by health systems in their workforce due to a volatile economy. Burnout and high turnover rates persist despite efforts to raise wages and strengthen hiring. The nursing shortage is a major issue, and efforts are being made to address the gender pay gap among physicians. On a positive note, there has been a record number of residency matches for 2023, providing insights into current labor trends in healthcare.That wraps up today's episode of Pharma and Biotech daily. Stay tuned for more important news and updates in

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Today, we have several updates and developments in the biopharmaceutical industry to discuss.First, Adlai Nortye, a biotech company, has raised funds through an initial public offering to support phase 3 testing of a cancer drug acquired from Novartis. The drug was previously studied by Novartis before being sold off.Moving on, there has been a decline in biotech IPOs, with Adlai Nortye's IPO being the 16th this year. The amount raised in the IPO was also lower than initially expected.In other news, PTC, a biotech company, is planning to lay off more staff after experiencing setbacks in Europe. This decision follows previous job cuts announced a few months ago.Interim results from a study called "Mariposa" showed that a combination of two Johnson & Johnson cancer drugs improved progression-free survival compared to AstraZeneca's widely used therapy.Additionally, drugs like Ozempic and Wegovy have the potential to revolutionize obesity treatment and our understanding of the condition.Now, let's move on to some other news. Madrigal Pharmaceuticals is planning a $500 million public offering as it aims to take the lead in the nonalcoholic steatohepatitis (NASH) market. This opportunity comes after Intercept Pharmaceuticals failed to emerge as the market leader in NASH.Alfasigma has acquired Intercept Pharmaceuticals in an $800 million cash deal. This acquisition represents a lifeline for Intercept as it has been facing challenges in the NASH market.Fabre-Kramer Pharmaceuticals has finally received FDA approval for its major depressive disorder (MDD) drug, Gepirone hydrochloride, after a decades-long quest. This approval opens up new treatment options for patients with MDD.Bionomics' post-traumatic stress disorder (PTSD) candidate has shown promising results in a Phase IIB study, leading to a 415% increase in the company's stock.GSK is projecting significant growth in its HIV business based on the success of its long-acting antiretroviral therapy Cabenuva. The company forecasts that its HIV business will reach up to $8.5 billion in sales by 2026.Now, let's move on to the FDA's recent guidance on simplifying updates to antimicrobial resistance tests. The guidance emphasizes the use of predetermined change control plans to streamline the process.Abbott's analysis of U.S. insurance claims suggests that GLP-1 drugs are a "modest accelerator" for continuous glucose monitoring systems (CGMs).In an opinion piece, Medtronic's Stacey Churchwell argues that artificial intelligence (AI) should be embraced in healthcare to streamline data and help tackle clinician burnout.As the possibility of a government shutdown looms, it is expected that medical device reviews will continue as normal. However, if a funding agreement is not reached by Sunday, the FDA could furlough nearly 20% of its staff.Moving on to FDA advisory committees, there are several key decisions being made. The Vaccines and Related Biological Products Adcomm will discuss which strain should be selected for next year's annual flu shots in the southern hemisphere. The Oncologic Drugs Adcomm will examine Amgen's supplemental new drug application for Lumakras, a treatment for non-small cell lung cancer patients with the kras g12c mutation.The article also highlights three recent FDA adcomm rejections and their implications for drugs in development and on the market. Effective communication from the pharma industry to the general public is crucial.Lastly, there are trailblazers from the PharmaVOICE 100 list who are driving innovation in the industry. Women's health is a growing sector with increased investments, and there are advancements in rare disease treatment and gene therapy.That's all for today's episode of Pharma and Biotech daily. Stay tuned for more updates and recommended articles for further reading.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.In today's episode, we have some exciting news from the industry. Let's get started.## "Best Practices for 2024 Biopharma Campaign Success"Today, we'll be discussing the importance of health audience segments in cost-effective media campaigns. This blog post provides measurement and activation best practices to optimize audience segments and improve campaign performance. It's based on hands-on experience in activating thousands of campaigns. If you're interested in learning more about how Crossix audience segments can reach consumers throughout the patient journey, feel free to contact the company. ## "2023 PharmaVOICE 100 Honorees"We have some exciting news about the upcoming release of the 2023 PharmaVOICE 100 honorees. These professionals are being recognized for their contributions to the healthcare industry, and they've been nominated by their colleagues. The honorees are selected based on their efforts to push boundaries and improve patient care. They're categorized into different groups, including standout executives, cancer care visionaries, clinical trial gurus, patient heroes, rare disease warriors, trailblazers, tech wizards, and brand and commercialization professionals. The honorees will be announced on September 19th. ## "Coca-Cola's New Flavor and Lunchables' Launch"In other news, Coca-Cola has launched a new flavor called Coca-Cola Y3000. This flavor was created with the help of artificial intelligence and is aimed at attracting younger consumers while still highlighting the brand's signature soda. Lunchables, a brand owned by Kraft Heinz, has also released a new product called Grilled Cheesies. To promote the launch, they've created ads that bring children's imaginations to life, depicting what happens in the microwave when heating the frozen product.## "McCann's Content Studio and Toyota's Multi-Agency Campaign"McCann, a global advertising agency, has streamlined its social and influencer services under a new content studio called McCann Content Studio. This move reflects the blurring lines between social media and creator strategies. Toyota, on the other hand, has launched a multi-agency campaign to unify its multicultural and mainstream messaging. The campaign aims to bring more cohesion to the automaker's marketing efforts around its new midrange Grand Highlander SUV.## "Simplifying Customer Purchases in the Medical Device Manufacturing Industry"Our next news is about an ebook titled "Simplifying Customer Purchases: The Medical Device Manufacturer's Guide." This ebook explores how technology and optimized purchasing experiences are crucial for success in the medical device manufacturing industry. It highlights the tools used by industry leaders, such as Thermo Fisher Scientific, to ensure a seamless sales process across multiple channels. The ebook discusses three key integrated applications that aid in simplifying customer purchases: CPQ Software, Document Automation, and Digital Commerce. It also includes success stories that demonstrate the tangible impact of these technologies in enhancing quoting processes, accelerating revenue generation, and elevating customer experiences.## "Barkley's 'State of the Whole Brand 2023' Report"Lastly, we have news about Barkley's "State of the Whole Brand 2023" report. This report aims to measure a brand's success by predicting it instead of looking at past performance. It's based on four years of data studying total brand performance, consumers, brands, and categories. Barkley claims to have generated a single number that can predict which brands will dominate the market and win the hearts of consumers. The report features insights and brand secrets from various successful brands. If you're interested in checking out the report to see how your own brand scores on the whole brand index, make sure to give it a read.That's

Today's Episode Dr. Raj speaks with Brian Loew about his patient engagement platform, Inspire. They discuss the origins and inspiration behind Inspire, exploring how it fosters a sense of community among its members, as well as the impact it aims to make in the years to come. Today's Guest  Brian Loew created Inspire in 2005 with the goal of accelerating medical progress by engaging patients and caregivers in safe, trusted online communities. For the past 17 years, he has grown the company to be the leading digital space for health, with more than 10 million visitors annually who join Inspire to discuss more than 3,000 health conditions. Brian has built a network of dozens of Non-profit partners including the American Lung Association, Mental Health America, and the Ovarian Cancer Research Alliance - who rely on Inspire for safe, moderated spaces where their members can receive trusted information and support.  Brian is a frequent speaker and writer on the topics of patient-centricity, the role of data in healthcare, health-focused social networks and digital medicine. He sits on the boards of the Robert Packard Center for ALS Research at Johns Hopkins, and New Jersey Goals of Care, and was a “Red Jacket” recipient from PharmaVOICE magazine for his contributions to the industry. Brian is a graduate of George Washington University. Check out Inspire here  About Dr. Raj Dr Raj is a quadruple board certified physician and associate professor at the University of Southern California. He was a co-host on the TNT series Chasing the Cure with Ann Curry, a regular on the TV Show The Doctors for the past 7 seasons and has a weekly medical segment on ABC news Los Angeles. Want more Dr. Raj? Check out the Beyond the Pearls lecture series! The Ultimate High Yield Bundle: The complete review of high-yield clinical medicine topics necessary for graduate medical education board exams including NBME, USMLE Steps 1/2/3, ITE and ABIM Boards. You can also listen to the Beyond the Pearls podcast. Check out our other shows: Physiology by Physeo Step 1 Success Stories The InsideTheBoards Study Smarter Podcast The InsideTheBoards Podcast Produced by Ars Longa Media To learn more about us and this podcast, visit arslonga.media. You can leave feedback or suggestions at arslonga.media/contact or by emailing info@arslonga.media. Produced by: Christopher Breitigan and Erin McCue. Executive Producer: Patrick C. Beeman, MD The information presented in this podcast is intended for educational purposes only and should not be construed as professional or medical advice. Learn more about your ad choices. Visit megaphone.fm/adchoices

Host Mike Sacopulos interviews Beth (Elizabeth) Garner, MD, MPH, who contributed her life and career story to the AAPL book, published in 2022, Lessons Learned: Stories from Women Physician Leaders. Garner is currently chief scientific officer of Ferring Pharmaceuticals, and president of the American Medical Women's Association (AMWA). She received joint MD and MPH degrees from the Harvard Medical and Public Health Schools and trained in obstetrics and gynecology at Brigham and Women's (BWH)/Massachusetts General Hospitals. She was a 2019 awardee of the PharmaVoice 100 Most Inspiring Individuals in the life sciences industry and received the 2022 Women in Science Award from AMWA. Physicians working to improve our healthcare system give us hope. Prepare to meet one of those extraordinary physician leaders. Dr. Garner's story and career trajectory should inspire other physicians, other women. @egarnermd Learn more about the American Association for Physician Leadership at www.physicianleaders.org

Host Mike Sacopulos interviews Beth (Elizabeth) Garner, MD, MPH, who contributed her life and career story to the AAPL book, published in 2022, Lessons Learned:  Stories from Women Physician Leaders. Garner is currently chief scientific officer of Ferring Pharmaceuticals, and  president of the American Medical Women's Association (AMWA). She received joint MD and MPH degrees from the Harvard Medical and Public Health Schools and trained in obstetrics and gynecology at Brigham and Women's (BWH)/Massachusetts General Hospitals. She was a 2019 awardee of the PharmaVoice 100 Most Inspiring Individuals in the life sciences industry and received the 2022 Women in Science Award from AMWA. Physicians working to improve our healthcare system give us hope. Prepare to meet one of those extraordinary physician leaders. Dr. Garner's story and career trajectory should inspire other physicians, other women. @egarnermd https://www.physicianleaders.org/publications/books/lessons-learned-stories-from-women-physician-leaders Learn more about the American Association for Physician Leadership at www.physicianleaders.org  

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW's Megan Thomas is in conversation with two experts when it comes to clinical trials. First up is Livia Ng, CEO and Founder of Neuroute. At just 24 years old, Ng is working on critical challenges in clinical trials, specifically in planning and recruitment, and has been building innovative solutions designed to benefit patients and researchers – with a focus on efficiency, transparency and diversity in clinical development. Thereafter, Thomas spoke with CEO of Trialbee, Matt Walz. Walz was recently selected in the 2022 PharmaVoice 100 for the company's innovative work in the space, and speaks about how real world data can help to boost diversity rates in clinical trials.

What is the best methodology for presenting your Company to investors, industry partners, and public funding organizations?Here is the answer: In this episode, Donna LaVoie presents her famous “15-slides-methodology” in great detail.Donna is a proven strategic communications leader in health and science innovation. She is a trusted advisor on strategic communications issues, especially around complex problems affecting multiple stakeholders. She brings a unique combination of public and investor relations expertise, including product launch experience.LaVoieHealthScience was launched in 2001 after a corporate career with signature biotech companies leading strategic communications functions during tremendous growth, product and business launches, and international geographic expansion.As an acknowledged leader in health science communications with public and investor platforms, LaVoieHealthScience is recognized as a top 30 independent healthcare agency in the US. The agency has received more than 35 awards for its client work. It is recognized by INC.5000 Hall of Fame – Fastest Growing Private Companies, Boston Business Journal's top Massachusetts PR firms, PharmaVOICE 100, and O'Dwyers.We are talking about:↪️ Why 15 slides are sufficient in corporate presentations↪️ Why you should have an Agenda slide↪️ Why an Appendix is important↪️ What is Better? Detail or Simplicity?↪️ The interplay of Problem and Solution↪️ Why the Team slide matters↪️ Why you need to adapt the presentation to your audience↪️ And much, much moreYoutube Video

Dr. Stuart Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the Board of Directors since the company's inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. PTC now has a footprint in more than 50 countries, with offices in 20 countries and more than 1,000 employees. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVoice's 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014. He earned a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.

Welcome to The Beauty Confidential Lounge, where I support you in embracing your Inner Rebel to ignite your soul's desires and own your magic.  I am your host Chaitali Desai.  This week join me as I interview conscious thought leaders, Kirstin Gooldy and Mark Stinson of Entelechy Leadership Stories. Kirstin is currently the CEO of Pure Entelechy (PE2.0) a technology company, innovator, and leader of AES (Alternative Educational System), board member of a technology consulting company, intuitive advisor to many senior level leaders and high-performance sales individuals and teams, podcast co-host of Entelechy Leadership Stories and the creator of many transformational classes, experiences and technologies designed to develop and evolve human consciousness. To connect with Kirstin Gooldy, visit: www.kirstingooldy.com https://www.linkedin.com/in/kirstingooldy/ Mark Stinson has earned the reputation as a “brand innovator” – an experienced marketer, persuasive writer, skilled facilitator, and venture catalyst. His work has included branding, advertising, and marketing strategy for health, science, and technology products. He is a recipient of the Brand Leadership Award from the Asia Brand Congress for global marketing efforts. He was included in the PharmaVoice 100 Most Inspiring People in the Life-Sciences Industry. He is the author of many business books and motivational journals. Mark is the host of two podcasts, “Entelechy Leadership Stories” and “Unlocking Your World of Creativity.” Connect with Mark: www.mark-stinson.com Entelechy Leadership Stories Podcast: Entelechy Leadership Stories on Apple iTunes Connect with Chaitali: The Beauty Confidential Lounge Community:  The Beauty Confidential Lounge Facebook: Chaitali B. Desai Instagram: chaitali_b_desai In this episode, Kirstin, Mark and I delve into conscious leadership, bringing Minority Voices to the table, highlighting the need to bring everyone's stories to the forefront. Please be sure to share this episode with your community to spread the word If you or someone you know has benefited from this episode! I am curious to hear all about your experience. Also, be sure to leave a review on iTunes and I will see you in the next episode.

Dr. Hayden is the CEO of Prilenia. He is an accomplished scientist and physician. He is a Killam Professor at the University of British Columbia and Senior Scientist at the Centre for Molecular Medicine and Therapeutics. He is also a Canadian Research Chair in Human Genetics and Molecular Medicine. Dr. Hayden was the President of Global R&D and Chief Scientific Officer at Teva from 2012-2017. He led the approval of Austedo for chorea in HD, the second drug ever to be approved for HD in the USA. Author of approximately 900 peer-reviewed publications, he has focused his research primarily on Huntington Disease, translational medicine, including genetics, lipoprotein disorders, predictive, personalized medicine and drug development. He also identified the first mutations underlying Lipoprotein Lipase Deficiency and developed gene therapy approaches resulting in the first approved gene therapy product (Glybera) in the world. Dr. Hayden is the recipient of numerous prestigious honors. Most recently, he was awarded the David Dubinsky Humanitarian Award from the American Friends of Soroka MedicalCenter. He was inducted into the Canadian Medical Hall of Fame in 2017. He was named one of PharmaVoice's “100 of the Most Inspiring People” (2015); awarded an Honorary Doctorate of Science by the Universities of Gottingen (2014) and Alberta (2009); the Luminary award by the Personalized Medicine World Conference (2014); the Diamond Jubilee Medal (2012) on behalf of HRH Queen Elizabeth II, the Killam Prize by the Canada Council of the Arts (2011), and the Canada Gairdner Wightman award (2011). Dr. Hayden is committed to empowering others. In addition to mentoring over 100 graduate students and postdocs, he is also a TED mentor. For more information about Prilenia, please visit  ABOUT US | Prilenia Therapeutics

Hi, and a warm welcome to The Elevate Business Podcast. We have the pleasure of introducing you to Michael Fergusson, the CEO and Founder of Ayogo.Michael was Ernst & Young's Social Entrepreneur of the Year and named the PharmaVOICE 100, a peer-nominated list of the 100 most inspiring people in Life Sciences. Ayogo's motto is: do your best work, change the world, and laugh every day. To that end, the Ayogo team has identified values that they feel are core to their mission: leadership, innovation, passion, teamwork, diligence, and kindness and as CEO, Michael is the steward of those values.For more on Ayogo: https://ayogo.com/

What is the secret to billing $28,000,000 in 14 years, including $12,800,000 in personal production? If your goal is to become a top biller or billing manager, you're going to love my interview with Michael Pietrack.  Michael was recommended to me on five separate occasions by previous podcast guests, so I made it my mission to get him on the show.  He's the Vice President of TMAC Direct which is the executive recruiting arm of The Medical Affairs Company based in Atlanta. On top of being a consistent top producer, Michael's achievements include becoming MRI's #1 Worldwide solo recruiter, being elected into the Pinnacle Society and becoming PharmaVoice's Top 100 Most Inspiring People in Pharma. Michael generously shared his approach and best practices as well as his mindset that drives him to success. Enjoy listening! Episode Outline and Highlights [2:30] From being a baseball player/coach to becoming a recruiter.  [4:15] The value of failure and other key drivers for Michael's success. [8:45] How to become a celebrity within your niche. [11:20] A very insightful discussion on branding. [14:10] Michael's best practices when creating videos as a differentiating factor. [20:05] How to effectively reach out to candidates to engage. [24:00] What are your thoughts on cold outreach? Hear Michael's winning mindset and approach. [32:00] Best practices on candidate outreach. [40:11] Candidate exclusivity - how to earn it instead of asking and other sourcing approaches. [47:07] What a typical busy desk looks like and how does Michael manage his time? [51:48] How to overcome phone fear and distraction. The Value of Failure Upon realizing that Michael had previous playing and coaching experience in baseball before transitioning to recruitment, I recalled what my friend Joel Slenning said about hiring athletes as recruiters. I have also interviewed successful recruiters and business owners who applied discipline from sports or even combat sports in their recruiting careers. I asked Michael's perspective, what is it about the athletic background that can add chances for success in recruiting? He gave his insights, “I would say the biggest commonality between all athletes is this ego drive that despite failure, you are going to succeed next time.” Michael added, “That's very important if you are going to be a resilient recruiter, you got to have that ingrained in you.” This is golden, considering that actual success is just the tip of the iceberg. What most people don't see are the number of times a recruiter or business owner must fail in order to learn and move forward.  Michael's Success Factors Michael also shared differentiating factors contributing to his success. Billing $12,800,000 in 14 years is more than just hard work. As Michael stated, it is a “compounding variety of things.” He gave two primary takeaways: Being more niched - Finding a niche, sticking to it and  “being a celebrity in that universe.” Branding and Marketing - hear Michael's epiphany while waiting in line at “In and Out Burger” and how it influenced his approach to recruitment.  Candidate and Client Outreach Best Practices On top of what Michael shared on sticking to your niche and being consistent with branding, he also shared practical approaches that can significantly increase your chances of success. From overcoming the fear of cold outreach, how to seek out candidates and earn exclusivity, to how he manages his time to make the most out of each day.  Our Sponsors This podcast is proudly sponsored by i-intro®.  i-intro® is an end-to-end retained recruitment platform. Our technology and methodology allows recruiters to differentiate themselves from the competition, win more retained business, bigger fees and increase their billings. Be sure to mention Mark Whitby or The Resilient Recruiter for a 25% discount. Book your free, no-obligation consultation here: www.recruitmentcoach.com/retained  Michael Pietrack Bio and Contact Info Michael Pietrack is a leading Pharmaceutical Industry recruiter from the US. His firm is called TMAC Direct, the executive recruiting arm of The Medical Affairs Company, which is the international leader in direct-hire and contract staffing for Medical Affairs.  Michael is known as one of the top five billers in the US, and because of that, he is a sought after speaker and trainer.  He runs a high performing desk, while overseeing several teams.  His hobbies include creative writing, Bible study, and spending time with his wife and three daughters. Michael on LinkedIn TMAC Direct website link TMAC Direct on Facebook TMAC Direct on YouTube Michael's volunteer work: JW.org website link People and Resources Mentioned Jordan Rayboy on LinkedIn Rob Bowerman on LinkedIn Sean Rigsby  on LinkedIn John Schlegel on LinkedIn Chris Schoettelkotte on LinkedIn Dave Murphy on LinkedIn Joel Slenning on LinkedIn The Go-Giver book by Bob Burg and John D. Mann  Connect with Mark Whitby Get your FREE 30-minute strategy call Mark on LinkedIn Mark on Twitter: @MarkWhitby Mark on Facebook Mark on Instagram: @RecruitmentCoach Related Podcast You Might Enjoy TRR#46 How to Run a Million Dollar Recruiting Firm From Your RV, with Jordan Rayboy TRR#32 How to Build a 7-Figure Search Firm with a Small Virtual Team, with Rob Bowerman TRR#82 How to Become a Big Billing Recruiter by Building Your Brand, with Sean Rigsby, Ep #82  TRR#65 Recruiting Success: How to Bill $700k+ While Achieving Work-Life Balance, with John Schlegel TRR#94 How to Create a Unique Value Proposition and Sell Retained Executive Search, with Chris Shoettelkotte  TRR#53 How to Scale Your Staffing & Recruiting Firm to $16,000,000, With Joel Slenning Subscribe to The Resilient Recruiter

Mike Rea, is founder of Protodigm, a contract skunkworks lab specializing in minimizing the risk of drug development by avoiding bias, premature specialization, and providing clients a universe of possibilities in which a drug could be brought to market. He talks about how the use of the skunkworks concept common in tech and engineering can innovate drug development. #Protodigm #DrugDevelopment Mike is the founder of Protodigm, a next generation CRO that innovates, invents, develops, and prototypes possibilities for drugs to be brought to market, as well as the CEO and founder of IDEA Pharma, a specialist in pharmaceutical product positioning and path-to-market strategies. He has delivered positioning and strategy for eight of the fifteen biggest drug launches in the last five years. After having been named to The Medicine Maker's Global Power List 100 from 2017 to 2019, in 2020 and 2021 he was added to the Global Power List 20: the top 20 inspirational medicine makers in biopharmaceuticals. PharmaPhorum has named him as one of the Top 10 Innovators in Pharma and PharmaVOICE awarded him with a lifetime Red Jacket as one of the 100 Most Inspiring People in Healthcare. He is the author of the Medical Marketing Manual: Branding Pharmaceuticals and the Pharmaceutical Innovation Index. Mike earned his bachelor's degree in genetics from the University of Newcastle-upon-Tyne.

Are you a tough leader or a resilience leader? Do you want to build more resilience and drive into your leadership and impact? Are you ready to accelerate your leadership? Our special guest Punit Dhillon answers these and other questions about leadership, resilience and personal drive. Punit Dhillon was nine when he almost drowned in a swimming pool. Twenty years later, he became a competitive swimmer and completed his first of several Ironman Triathlons. Punit lives by the philosophy of using adversity as fuel to exceed all expectations. At thirty, Punit was one of the youngest biotech CEOs in the life sciences industry, and just five years later, he became a NASDAQ CEO for a publicly traded biotech company.  Punit is currently the Chair and CEO of Skye Bioscience, a public pharmaceutical company. He's also the Co-founder, former President, and CEO of OncoSec, a biotechnology company pioneering new technologies to fight cancer. Punit has been recognized as one of PharmaVOICE 100's top CEOs and as a finalist for the EY Entrepreneur Of The Year™. Punit is also the author of Catapult: How to Think Like a Corporate Athlete to Strengthen Your Resilience, an insider's look at the lessons we learn by turning obstacles into opportunities. Taking you through his twenty years of global business experience, Punit shares ten principles for a purpose-driven life and career, linking together the athletic strengths that will help you succeed. The Leadership Junkies Podcast is brought to you by Cardivera.com. Show Notes Episode highlights… Leadership, business and resilience lessons from being an ultra-athlete Ways that adversity can help you grow if you're intentional about the learning Understanding resilience and building more of it in your life Impact of family culture and upbringing in the foundations of resilience Importance of doing post-mortems to better learn and grow from experiences Resilience is not about deflecting the challenges that you that you have, it's about taking them on and absorbing them, and then rebounding as fast as you could Beware Rocky style resilience (taking a beating and staying standing) Resilience is not false armor or mental toughness Learning about lessons from riptides Shifting from confident decision making in leadership to a more mindful approach and supporting your people What does it mean to serve the people on your team The critical need of coaching in leadership Differently understanding “high performer” and being clear on what it means (high performer must be holistic) Taking time to step back and appreciate all we've already achieved Role of visualization in achievement and resilience Leadership lessons from the movie Spy Game Resources: Punit Dhillon (hello@punitdhillon.com) Punit Dhillon Website Catapult: How to Think Like a Corporate Athlete to Strengthen Your Resilience Book The Leadership Junkies Podcast Cardivera

The 40-year trajectory for your career: Punit Dhillon, executive, investor, and new author, joins host Gregg Garrett for a discussion on being an effective corporate athlete and catapulting your career. He of course shares his Top Three who include his wife who acts as the yin to his yang, a mentor who Punit has followed through his 20-year career, a business partner who backstops him every step of the way, and an executive coach who helped him to re-realize the importance of the coaching relationship in achieving excellence. And you have to hear what he says about making a routine around the first hour of your day.   About Punit Dhillon Punit Dhillon is the Chair and CEO of Skye Bioscience Inc., a public pharmaceutical company. He is the Co-founder, former President, and CEO of OncoSec, a biotechnology company pioneering new technologies to fight cancer, and the Co-founder of the registered charity, YELL Canada. Punit has been recognized as one of PharmaVOICE 100's top CEOs and as a finalist for the EY Entrepreneur of the Year ™. He lives in San Diego with his wife, Nina, and their two daughters. About “Catapult: How to think like a corporate athlete to strengthen your resilience” Punit Dhillon was nine when he almost drowned in a swimming pool. Twenty years later, her became a competitive swimmer and completed his first of several Ironman Triathlons. Punit lives by the philosophy of using adversity as fuel to exceed all expectations. At thirty, Punit was one of the youngest biotech CEOs in the life sciences industry, and just five years later, he became a NASDAQ CEO for a publicly traded biotech company. Punit's pioneering tenacity is shared by other extreme athletes and high-achieving corporate professionals who understand that we never truly know what we can accomplish until we push our limits. In Catapult, Punit gives you an insider's look at the lessons we learn by turning obstacles into opportunities. Taking you through his twenty years of global business experience, Punit shares ten principles for a purpose-driven life and career, linking together the athletic strengths that will help you succeed in the business world. With the right training and mindset, adversity becomes your motivation. This book will show you how to challenge the status quo, leave your legacy, and truly change the world. Show Highlights During this episode:  14,600 days or 480 months or 40 years: The standard career trajectory [1:05] Honest current headlines [4:00] Welcome guest, Punit Dhillon [5:44] The “Top Three” Nina Dhillon: Punit's wife who is the ying to his yang [15:23] Avtar Dhillon: Punit's uncle and mentor he has followed throughout his career [23:12] Tu Diep: Punit's business partner who backstops him every step of the way [37:12] Judy Brooks: Punit's executive coach who highlights the importance of the coach relationship in achieving excellence [45:04] Transformation & Disruption Punit's Book: Catapult: How to think like a corporate athlete to strengthen your resilience [51:52] You have to hear this… Punit's Tip: Make a routine around the first hour of your day [1:00:58] Additional Information Contact Punit Dhillon: Punit's LinkedIn Punit's Website Punit's Twitter Contact Gregg Garrett: Gregg's LinkedIn Gregg's Twitter Gregg's Bio Contact CGS Advisors: Website LinkedIn Twitter

Mark Stinson is a strategist for brand innovation – an experienced marketer, creative group facilitator, and venture catalyst. He is the founder of Bioscience Bridge and the author of five books on branding and creativity in health, science, and technology marketing.Mark is a frequent speaker, trainer, and facilitator for sales meetings, advisory boards, and strategy workshops. He has received the Brand Leadership Award from the Asia Brand Congress for global marketing efforts, and he is included in PharmaVoice's 100 Most Inspiring People in the Life-Sciences Industry.Mark and his wife, Jenny, have five children and a golden retriever. They live in Garden City, Idaho.During this interview, we discuss…What it means to be an "activated" patientHow to measure “activation"The 83bar processHow to make patients feel heardHow Mark's company has evolved after Covid-19After the interview…Patient Activation: 4 Steps Proven to Move Health Care Consumers From Awareness to Action https://www.amazon.com/Patient-Activation-Proven-Consumers-Awareness/dp/1722919493Visit 83bar, the Patient Activation company https://www.83bar.comVisit Mark's website https://www.mark-stinson.com/Listen to Mark's podcast https://markstinson.captivate.fmFollow Mark on LinkedIn https://www.linkedin.com/in/stinsonmark=============Jennifer DreanSuccess StrategistDeliberate Directions + Executive Business Coaching + Training Center3003 W Main Street, Suite 110, Boise ID 83702(208) 350-6551Website https://www.deliberatedirections.comLinkedIn https://www.linkedin.com/in/jennifer-drean-86003a19/Podcast https://podcasts.apple.com/us/podcast/deliberate-leaders-podcast-with-allison-dunn/id1500464675

Anne Quinn Young, MPH, Brand President of the MMRF discusses CureCloud, their latest platform designed to provide myeloma patents with their own genomic profile while building a database that combines genomic insights with clinical data to identify trends and support further developments. The CureCloud mission is to find and develop cures for all myeloma patients based on the fact that all patients can contribute to cures and each patient can benefit from the masses. Anne Quinn Young, MPH, is the Brand President at the MMRF and is responsible for overseeing the strategy and execution of the organization's marketing, communications, patient engagement, and fundraising efforts in support of the organization's mission to accelerate precision medicine and a cure for every patient. Anne has been named to the PharmaVoice 100, and represents the MMRF on a number of working groups and committees including the Direct-to-Patient (DTP) solutions team at the Harvard Business School (HBS) Kraft Precision Medicine Accelerator and the Cancer Support Community Frankly Speaking About Cancer: Multiple Myeloma National Advisory Board. She has co-authored a number of peer-reviewed abstracts and publications on the MMRF Precision Medicine Model and identifying knowledge gaps and opportunities to improve patient empowerment and engagement in optimizing their own outcomes. Prior to joining the MMRF in 2002, she was a consultant in the Healthcare Practice of Datamonitor, a global market research and business intelligence company. She previously worked in healthcare public relations at Burson-Marsteller and the Chandler Chicco Agency, following a postgraduate internship at the Department of Justice, Antitrust Division. Anne has a Masters of Public Health from the Mailman School of Public Health of Columbia University and graduated cum laude from Dartmouth College with a Bachelor of Arts in Government. #MultipleMyeloma #MMRF #CureCloud

This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: https://www.catalysthealthtech.com/ (CLICK HERE) --- Driven by a relentless passion for improving patient care via the convergence of biology and technology, our next has dedicated himself to curating global communities that are positively moving industry forward.  Dr. Amir Kalali, Co-Chair of the Decentralized Trials and Research Alliance, and Chairman and Chief Curator of the CNS Summit, joins us to discuss his storied career of leading global drug development and health care services in the neuroscience industry and how his experiences have propelled his passion for convening other industry-leading pioneers to improve patient care.  Join us for this action-packed conversation and call-to-action as we continue to work together to move the healthcare industry forward. Let's go!  Episode Highlights: Dr. Kalali's storied career and globally leading initiatives Why Dr. Kalali has dedicated himself to curating communities to move healthcare forward  How to get involved in Dr. Kalali's initiatives About our Guest:  Dr. Kalali is a physician scientist, recognized globally as a leading innovator at the intersection of life sciences and technology, and a convener of collaborative high impact forums. He is a board director of both private and publicly traded companies, and advises companies in the life sciences and technology sectors, universities and investment groups. Dr. Kalali is the Co-Chair of the Decentralized Trials and Research Alliance (DTRA), Chairman and Chief Curator of the CNS Summit, a forum focused on the future of life sciences, and was the Founding Chairman, and sits on the Executive Committee of the International Society for CNS Drug Development (ISCDD), one of the first independent non-profits to bring together leaders in drug development to collaborate, and on the Executive Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM). He is Professor of Psychiatry at University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development., published by Cambridge University Press. He has authored over 250 peer-reviewed publications, and numerous book chapters. He has been involved in initiatives by the Institute of Medicine, as well as the NIH FAST and the NIH NCATS programs. Previously, for almost 20 years, he was the Global Head of the Neuroscience Center of Excellence at Quintiles, now known as IQVIA. In this role, he led the enterprise-wide strategy for neuroscience, encompassing drug development and health care services. He was responsible for numerous successful drug development programs that have led to dozens of approved new treatments for patients. Dr. Kalali regularly speaks at national and international scientific meetings on topics including drug development, clinical trials, innovation, technology, digital medicine, biohacking, and health. Dr. Kalali's contributions have been recognized by life sciences media including The Medicine Maker's Power List and the PharmaVOICE magazine's Inaugural Red Jacket award, recognizing those who have been most lauded by their peers. Links Supporting This Episode: CNS Summit website: https://cnssummit.org/ (CLICK HERE) DTRA website: https://dtra.org/ (CLICK HERE) Dr. Amir Kalali LinkedIn page: https://www.linkedin.com/in/amirkalali/ (CLICK HERE) Dr. Amir Kalali Twitter page: https://twitter.com/akalali (CLICK HERE) Clubhouse handle: @mikebiselli Mike Biselli LinkedIn page: https://www.linkedin.com/in/mikebiselli (CLICK HERE) Mike Biselli Twitter page: https://twitter.com/mikebiselli (CLICK HERE) Visit our website: https://www.passionatepioneers.com/ (CLICK HERE) Subscribe to newsletter: https://forms.gle/PLdcj7ujAGEtunsj6 (CLICK HERE) Guest... Support this podcast

Over the past two decades, digitization, technology, and software have contributed to the life sciences industry's rapid disruption. However, this was just the beginning of pharma's data and software-led transformation. Hear Jassi Chadha, President, and CEO of Axtria, explain how data, artificial intelligence (AI), and software will become the industry's primary disruption drivers as data variety, volume, and velocity continue growing. Whether companies succeed in 2025 and beyond will depend on how well they leverage AI and analytics for deriving valuable, data-driven insights. Tune in as Jassi describes how years of digitization at Moderna wired the company to lead the COVID-19 vaccine race and what the Pfizer-Israel deal reveals about the companies' access to data.  In This Episode, We Cover:  [02:30] The industry's disruptions in the past two decades and their primary drivers.  [04:40] The role of data, AI, and software in disrupting the future industry.  [07:00] The evolution of business needs and models; pharma and life sciences companies' need for intelligence systems.  [11:20] Moderna's digital edge which leads to their rapid vaccine development. [15:10] Jassi's thoughts on Israel's data deal with Pfizer.  Key Takeaways:  Companies must lead with AI to stay relevant going forward as data volume, variety, and veracity increase. Decision accuracy and velocity will become the most significant competitive advantage.  As business and monetization models continue evolving rapidly, commercial success will depend entirely upon an organization's data and software acumen. These two key components will lead to true digital transformation in the future.   Moderna enabled their rapid vaccine development due to their digital-first approach and ability to operate as both a technology and biology company. On the other hand, the Pfizer-Israel deal indicates the growing importance for life sciences to access data.  Meet Jassi Chadha:  Jassi is an entrepreneur, a highly regarded data scientist, and an influential thought leader in the rapidly-evolving data analytics and artificial intelligence (AI) fields. Jassi currently serves as the President and CEO of Axtria - one of the life sciences industry's most prominent global players that serves clients in 75+ countries. Previously, Jassi was the co-founder and CEO of marketRx, which Cognizant Technology Solutions acquired. Jassi is an advisor, board member, and investor in several companies and diverse organizations, including Ocular Therapeutics, SpectraMedix, Estee Advisors, New Jersey Technology Council, TiE Global, PAN IIT, Panjab Digital Library, and Sikh Research Institute. He is currently a member of the Second District Advisory Council of the Federal Reserve Bank of New York. Some of the most aspirational lists have featured Jassi and his companies, including E&Y "Entrepreneur of the Year," the Pharmaceutical Management Science Association (PMSA) "Life Achievement Award," PharmaVOICE 100, Salesforce's "Trailblazing Entrepreneurs," Inc. 500, Deloitte, NJBIZ, SmartCEO, Future 50, Red Herring, and several other growth, product, culture, and technology awards. Resources:  Jassi on LinkedIn:https://www.linkedin.com/in/jchadha/ IDC's Global DataSphere forecast shows continued steady growth in the creation and consumption of data [internet]. IDC, May 8, 2020 [cited Mar. 15, 2021]. Available from: https://www.idc.com/getdoc.jsp?containerId=prUS46286020 Estrin D. Vaccines for data: Israel's Pfizer deal drives quick rollout – and privacy worries [internet]. Jan 31, 2021 [cited Mar. 28, 2021]. Available from: https://www.npr.org/2021/01/31/960819083/vaccines-for-data-israels-pfizer-deal-drives-quick-rollout-and-privacy-worries Ready to hear more from life sciences leaders? Click here to access our Axtria Insights resource library– your go-to for expert insights, industry perspectives, and modern business approaches.

Dr. Clare Grace, Chief Patient Officer at Parexel, a leading Clinical Research Organization (CRO) discusses a report titled "Discussions on Diversity" that includes key takeaways regarding candid discussions on the topic of racial and ethnic diversity in clinical trials. As Chief Patient Officer for Parexel, Dr. Grace leads Parexel's global patient advocacy and site efforts, including patient engagement strategies and efforts to enhance clinical trial diversity as well as new, innovative approaches to help teams and customers work more effectively with investigative sites. Most recently she served as Vice President, Site & Patient Access at Syneos Health, formerly INC Research, where she oversaw all departments responsible for patient engagement, feasibility, site identification, strategic site relations and investigator payments. Her experience also includes senior-level patient and site-focused leadership roles with PPD, Astra Zeneca and Antisoma. With more than 20 years of experience in the CRO and biopharmaceutical industries, Dr. Grace was recognized in 2018 by PharmaVoice as one of the top 100 most inspirational leaders in the pharmaceutical industry. She earned a doctorate in Molecular Oncology from the University of Manchester Institute of Science and Technology and a bachelor's degree in applied biochemistry from Liverpool John Moores University, both in England. Dr. Grace is active in several global and national-level advisory groups, including the Society for Clinical Research Sites (SCRS) and the SCRS Leadership Council. #Parexel

Anne Quinn Young, MPH, is the Brand President at the MMRF and is responsible for overseeing the strategy and execution of the organization's marketing, communications, patient engagement, and fundraising efforts in support of the organization's mission to accelerate precision medicine and a cure for every patient. Anne has been named to the PharmaVoice 100, and represents the MMRF on a number of working groups and committees including the Direct-to-Patient (DTP) solutions team at the Harvard Business School (HBS) Kraft Precision Medicine Accelerator and the Cancer Support Community Frankly Speaking About Cancer: Multiple Myeloma National Advisory Board. She has co-authored a number of peer-reviewed abstracts and publications on the MMRF Precision Medicine Model and identifying knowledge gaps and opportunities to improve patient empowerment and engagement in optimizing their own outcomes. Prior to joining the MMRF in 2002, she was a consultant in the Healthcare Practice of Datamonitor, a global market research and business intelligence company. She previously worked in healthcare public relations at Burson-Marsteller and the Chandler Chicco Agency, following a postgraduate internship at the Department of Justice, Antitrust Division. Anne has a Masters of Public Health from the Mailman School of Public Health of Columbia University and graduated cum laude from Dartmouth College with a Bachelor of Arts in Government. Support the show: https://theanswersandiego.com/radioshow/8349 See omnystudio.com/listener for privacy information.

This episode’s Community Champion Sponsor is Adaptrack. To learn how Adaptrack is helping healthcare avoid malpractice, burnout & administrative risks: https://www.adaptrack.com/ (CLICK HERE) --- Named as one of the top Top 50 Health Influencers by PR Week and Fast Company’s “50 People to Watch in the New World of Work,” our next guest is a globally recognized healthcare innovation leader that inspires so many others to create impactful solutions that can bring positive change to the healthcare industry! Gil Bashe, Managing Partner of Global Health for Finn Partners, joins us to discuss his journey from the battlefield to the boardroom and his mission to inspire others to advance people’s well-being and access to health innovation.  Additionally, Gil shares why he continues to seek to mobilize communities of influence through his work at Finn Partners and as a health policy author for Medika Life on Medium, as well as where he sees healthcare innovation heading into the future and how and why you should be a part of this exciting movement.  Join us for this energy-filled and inspirational message from Gil as we continue to work together to move the health of our communities forward! Episode Highlights: Gil’s time spent as a military medic continues to fuel him to innovate healthcare Where and how all of us can help the healthcare industry innovate Areas of significant opportunity for innovation from Gil’s perspective What we need to contemplate while the healthcare industry continues to dramatically change What Gil and his team are dedicated to at Finn Partners Opportunities to engage with Gil and his international work and mission About our Guest:  Champion for health innovation to sustain life and improve patient care, Gil has been tapped by PharmaVOICE "as one of the 100 most inspiring people in healthcare;" included in the Fast Company “50 People to Watch in the New World of Work”; chosen as a MM&M Top 10 Innovation Catalyst; by PRWeek/MM&M as a Top 50 Health Influencer;" noted by Medium's Medika Life as a "Top 50 Healthcare Influencer;" recognized by the PRSA Health Academy with its "Excellence in Public Relations" award, PM360 with its "Trailblazer Lifetime Achievement Award" and selected for the PR News "Hall of Fame." Gil has led four top agencies cited by PRovoke Media (The Holmes Report) as "Healthcare PR Agency of the Year" winners. He is a Medika Life Medium "Being Well" author and a Top 10 digital/health influencer. He serves on a number of national industry and patient advocacy boards. Gil has led agency teams that contributed to numerous global med/tech and biopharma blockbusters in cancer, diabetes, heart, respiratory, women's health and non-communicable and orphan disease therapies. His background in payer, provider, policy, pharma marketing and patient-advocacy communications enables him to integrate ideas that impact patient access to health innovation. Dedicated to inspiring colleagues to succeed for clients and their customers, he was Group Company CEO, CommonHealth, and at WPP Group sister-company Hill + Knowlton, EVP, Worldwide Health Practice Director - its first Global Practice Head. He served as CEO of Health!Quest Global Communication Partners, a GTCR-backed private-equity firm now with $10 billion in active assets. Gil held leadership positions with New York-based agencies Makovsky, Medicus, (today part of Publicis Healthcare), and at pioneering integrated health-marketing agency Sutton Healthcare Group (acquired by Medicus). As a drug development policy and environment lobbyist, he served as a director with the New Jersey Health Products Council representing the health products industry. He completed his military service as a paratrooper combat medic and staff sergeant.  Links Supporting This Episode: Finn Partners website: https://www.finnpartners.com/ (CLICK HERE) Medika Life Author website: https://medika.life/ (CLICK HERE) Gil... Support this podcast

Laurie Cooke is currently the president and CEO of the Healthcare Businesswomen Association (HBA), a non-profit organization dedicated to furthering the advancement and impact of women in the business of healthcare. Under her leadership, the organization has grown substantially to a community of nearly 60K and 150 companies, with a presence in 55 locations across the US, Canada and Europe and online communities starting in Latin America and Asia Pacific.  Laurie has been recognized as Mentor of the Year by the American Society of Association Executives, twice honored as 100 Most Inspiring People in the Life Sciences by PharmaVOICE, and Healthcare Champion by National Association of Female Executives. Laurie's career spans global roles across several industries and continents holding executive roles on the Project Management Institute's (PMI) executive management team; international teams in process improvement, team effectiveness and project management at Hoechst, Hoechst-Roussel, Hoechst Marion Roussel, and Aventis Pharmaceuticals Inc; and hospital pharmacist roles in Seattle, WA. In this episode, we discuss: ·     How the focus on female leadership shifted from readying women to trying to tackle the systematic issues that kept women off the corporate ladder. ·     Helping overall company performance by teaching men to not be afraid of the power shift to a more diverse team. ·     Why ignoring the lack of female representation in the business of healthcare will cause it to stall out and fail in the future. ·     How to embrace a full model of leadership- and not place it on gender. I hope you will find this episode as exciting and informative as I have. Please let me know your thoughts!   Connect with Laurie Cooke LinkedIn: https://www.linkedin.com/in/lauriecooke/ Twitter: https://twitter.com/lcooke9 Facebook: https://www.facebook.com/laurie.cooke.HBA Instagram: https://www.instagram.com/lcooke9/   Connect with Dr. Sharon Melnick Website: https://www.sharonmelnick.com/ LinkedIn: https://www.linkedin.com/in/sharonmelnick/ Instagram: https://www.instagram.com/drsharonmelnick/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Mark is founder and principal of Bioscience Bridge, LLC, a conscious brand consultancy. His work has included market research, customer journeys, product branding and marketing strategy for health, science, and technology products. He is the author of many business books, including, Patient Activation, ForwardFast Branding, Customer CHEMistry, N-of-8 Creative Groups, and A World of Creativity. Mark hosts two weekly podcasts: Entelechy Leadership Stories and Unlocking Your World of Creativity. Mark has been included in the PharmaVoice 100 Most Inspiring People in the LIfe Sciences Industry. Connect with Mark Stinson:https://www.mark-stinson.comOn this episode:Amber in joined by Mark Stinson for a conversation on potential, confidence, and the keys to unlocking what you're fully capable of.Tweetable Quotes:"Our full potential is already inside of us... we just need the right environment for it to bloom." -Mark Stinson"Every entrepreneur comes to the point where we accept that we can't beat the world into what we would like it to be. We have no choice but to adapt at some point." -Amber Fuhriman"We often cut out the human element in our marketing profile to appeal more professional. We forget it's that element that makes people listen in the first place." -Amber Fuhriman"Peel the layers back. Find out who your customer is. What makes them tick. What makes them happy." -Mark StinsonConnect with other incredible people looking to break out of the corporate mindset by joining the More Than Corporate Facebook group: http://bit.ly/2MuWn53 See acast.com/privacy for privacy and opt-out information.

Ayogo has been named one of the top 100 most innovative mHealth companies in the world - twice. And it's easy to see why … Ayogo works with some of the biggest therapeutics companies in the world to build applications that use well-established principles of perceived self-efficacy and behaviour change to promote treatment adherence and improve health outcomes. They employ techniques used in game development in their designs, among which is the concept of adapting to overcome a challenge in an environment that is relatively low-risk. What's really exciting is that their approach can be applied with great success in a wide range of therapy areas including in sleep medicine, diabetes, MS, dialysis, and even social interventions, among many others. Michael Fergusson is an entrepreneur, innovator, philanthropist and the CEO of Ayogo. He also serves on several Boards of Directors, including Innovate BC, a Provincial Crown Agency, and the Electric Company Theatre, one of the most innovative theatre companies in the world. In 2012, Michael was Ernst & Young Social Entrepreneur of the Year and was also named to the PharmaVoice 100, a list of the 100 most inspiring people in Life Sciences. He was also a grand champion and a multi-gold medalist at the Western Canadian Martial Arts championships. We hope you enjoy this conversation! Also check out the full episode on our Youtube Channel, MedTech Trends, here: https://youtu.be/hde80WNFQTQ Find out more about Michael and Ayogo: Home: https://ayogo.com/ Twitter: https://twitter.com/ayogo Facebook: https://www.facebook.com/ayogo Youtube: https://www.youtube.com/channel/UCowC... Ayogo: https://www.instagram.com/ayogoteam/

Craig Lipset is the founder of Clinical Innovation Partners, providing advisory and board leadership with pharma, tech and venture capital to bring vision and driving action at the intersection of research, digital solutions, and patient engagement. He is co-chair for the Decentralized Trials & Research Alliance, serves on the Board of Directors for the Foundation for Sarcoidosis Research and the MedStar Health Research Institute, as well as on the Editorial Board for Therapeutic Innovation & Regulatory Science. Craig is Adjunct Assistant Professor in Health Informatics at Rutgers University, and Adjunct Instructor in the Center for Health + Technology at University of Rochester. Craig was the Head of Clinical Innovation and Venture Partner at Pfizer, on the founding Operations Committee for TransCelerate Biopharma, and on the founding management teams for two successful startup ventures. Craig has been listed among the PharmaVOICE most inspiring people in the life sciences (Red Jacket hall-of-fame), Pharmaceutical Executive's Emerging Leaders, CenterWatch Top 20 Innovators in Clinical Trials, and the AlleyWatch Who's Who in eHealth.

Welcome to Pass the Secret Sauce. Today's guest is Mark Stinson who has earned the reputation of a brand innovator – a strategist, creative facilitator, and venture catalyst. Mark is the founder and principal of Bioscience Bridge, LLC, a conscious brand consultancy. His work has included market research, customer journeys, product branding, and marketing strategy for health, science, and technology products. He is the author of many business books, including Patient Activation, ForwardFast Branding, Customer CHEMistry, N-of-8 Creative Groups, and A World of Creativity. Mark hosts two weekly podcasts: Entelechy Leadership Stories and Unlocking Your World of Creativity. Mark has been included in the PharmaVoice 100 Most Inspiring People in the Life-Sciences Industry. In this episode we discuss: His first introduction to business ━ selling magazine subscriptions [5:33] The image of being the paperboy, marketing their family business [6:55] What he learned in their business [8:30] His career overview [9:43] Getting the brand mindset and helping clients [10:47] The importance of a brand, elevating their brand's messaging [13:30] Explaining the ForwardFast Branding [16:05] What are the 6 attributes of a brand, Customer CHEMistry [19:30] How to map out things in different scenarios with a script [22:46] Keeping a contingency mindset [26:10] Best way to connect with Mark Stinson [30:33] Quotable Quotes The great brands had a quality about them. That if you document why your product is different, why that difference is meaningful to the customers and why is that relevant to their daily life or their business, then you're a long way away. Links to sources and tools Connect with Mark in LinkedIn: Personal Linkedin: https://www.linkedin.com/in/stinsonmark/ Company: https://www.linkedin.com/company/bioscience-bridge-llc/ Check's Mark's services: http://mark-stinson.com Thanks for listening. Don't forget to like us on Facebook: https://www.facebook.com/passthesecretsauce to get updates on new episodes. If you haven't already, please follow and leave a review for our podcast, we'll really appreciate it. And as always, don't forget to pass the secret sauce. Support our podcast If you're a fan of the show, there are three simple things you can do to support our work: Subscribe, rate and review: https://podcasts.apple.com/us/podcast/pass-the-secret-sauce-by-matt-shields/id1506940483 the podcast on iTunes or wherever you subscribe. Tell a family member, friend, or colleague about the show. Subscribe to us on YouTube: https://www.youtube.com/channel/UCJ5eItxsGWyGKC91zd1pzbA and follow us on LinkedIn: https://www.linkedin.com/company/pass-the-secret-sauce-podcast This podcast is hosted by ZenCast.fm

The FDA Group's CEO, Nick Capman, sits down with Mark Shapiro, a Partner with biopharmaceutical consulting firm Pharma Initiatives, to discuss outsourcing and insourcing models in the current clinical R&D environment, and what to consider when selecting the right model or mix of models for a project. Download the corresponding white paper and put these insights into practice: A Modern Guide to Clinical Operations Resourcing. Mark is widely recognized as an expert on the business of clinical research and is frequently quoted in the press, including Outsourcing Pharma, PharmaVoice, and CenterWatch. His comments have also been featured in the New York Times and Raleigh News & Observer on topics pertaining to the business of drug development. His focus at Pharma Initiatives is growth and innovation strategies in clinical research, development, and medical affairs. He has led strategic planning, growth, and change management initiatives at many pharmaceutical, biotech, and clinical research organizations. Prior to joining Pharma Initiatives, Mark was SVP, Operations at a global CRO, where he was responsible for an operations team of about 500 drug development professionals in more than 30 countries, and a portfolio of more than 100 active clinical trials. He was previously a management consultant at Campbell Alliance in the Clinical Development and Medical Affairs Practice, where he worked with many global CROs and biopharma companies on R&D innovation strategy. Mark is a pharmacologist, holds an MBA from Duke University's Fuqua School of Business, and has received numerous certifications in clinical research, regulatory affairs, and healthcare management. Need RA/QA/Clinical project or resourcing support? The FDA Group helps thousands of life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more and get the conversation started: www.thefdagroup.com.

TOPIC: Pharma Forecast 2021 LENGTH: 29:46PANELISTS: R.J. Lewis and Amy TurnquistHOST: Jason E. CarrisToday’s episode of AMM Conversation, the official podcast of the Association of Medical Media, continues our exploration of the emerging trends in medical media.Our guests today:R.J. Lewis is founder and CEO of eHealthcare Solutions. EHS exclusively represents 85 high-quality healthcare publishers. EHS has been named a PM360 Trailblazer Company of the Year, and RJ previously was named to the PharmaVOICE 100 list.Amy Turnquist is Executive Vice President of Digital at eHealthcare Solutions. Amy is a recognized thought leader and frequent speaker at industry events, including eyeforpharma, Digital Phama East, and the Digital Health Coalition. She serves on AMM’s Board of Directors.Topical Timestamps: 1:25 RJ thinks that, during the Covid-19 pandemic, Pharma as an industry has regained much of the credibility it lost in years past5:55 Amy explains innovation has been forced upon marketers and publishers, and the pandemic has forced Pharma to loosen its grip on new and innovative ideas9:35 Campaign measurement is table stakes, and not just impressions or clicks or engagements, but they want to know exact physicians10:12 Amy says Pharma is starting to understand innovations in 2020 are now standard in 2021, including strong budgets for native advertising and video advertising12:25 RJ expects clients to require real-time campaign data in the not-too-distant future14:04 Amy explains that if your campaign can’t be measured, you will be phased out18:41 Amy says HCP marketing is quickly moving to an e-commerce model, with ROI and cost-per-acquisition the new KPIs20:10 RJ says the cookie-less future is a “wonderful opportunity” for HCP publishers24:49 Amy outlines use cases for native advertising, and what she calls the “Moment of Next”26:37 RJ says native advertising is performing 3X better than other digital tacticsResources: Find additional medical media resources via AMM's Knowledge Exchange Center.Next: TrendMD's Paul Kudlow discusses emerging trends in digital marketing. The easiest way to know when the next season drops is to subscribe or follow the podcast.  Contact us:  AMM Conversation is the official podcast of the Association of Medical Media. Send questions and comments about this podcast series to jcarris525@gmail.com.

It is now well proven that accurate diagnoses help prevent the spread of COVID-19, but there is still much work needed in this arena to help battle this deadly virus. In this episode, we have Diagnostics Evangelist Mara Aspinall with us to more deeply share the vital role of diagnostics and their power to help us overcome this crisis.  Mara is a pioneering healthcare industry leader and is the Managing Director of BlueStone Venture Partners, a venture fund investing in life science technology companies, and the Co-founder of the Biomedical Diagnostics Program at Arizona State University. During our time together, Mara highlights the significance of diagnosis and testing and how she helps lead the Arizona State University's COVID-19 Diagnostics Commons' critical efforts, in conjunction with the Rockefeller Foundation, which is helping to empower many global organizations to work together to overcome this public health catastrophe.   Episode Highlights: Diagnostics in the midst of the COVID-19 pandemic Overview of ASU’s COVID-19 Diagnostics Commons The partnership between Arizona State University and the Rockefeller Foundation COVID-19 Diagnostics Commons resources, including their new T3 Blog About Our Guest: Aspinall is a healthcare industry leader and pioneer committed to active civic involvement. She is Managing Director and Co-Founder of BlueStone Venture Partners, a venture fund investing in life sciences technology companies in the US Southwest. She is also Managing Director of the Health Catalysts Group, a consulting firm dedicated to the growth of diagnostics and health information technology firms, publishing the popular Health Catalysts Diagnostics Year in Review. She is a member of the Board of Directors of Abcam plc (ABC), Allscripts (MDRX), Castle Biosciences (CSTL), Orasure (OSUR), and Blue Cross Blue Shield Arizona. Most recently, Aspinall was certified in Cybersecurity Oversight from Carnegie Mellon University. Aspinall is co-author of The Rockefeller Foundation National COVID-19 National Testing & Contact Tracing Action Plan and curator for TestingCommons.com – the most comprehensive database of COVID related tests on the market or in development worldwide.  As President and CEO of Ventana Medical Systems, a billion-dollar division of The Roche Group, (now Roche Tissue Diagnostics) Aspinall led her world-class team to new financial success, more than two dozen major instrument and assay launches as well as global leadership in companion diagnostics.  Previously, Aspinall spent 13 years at Genzyme Corporation where she served as President of Genzyme Genetics and Genzyme Pharmaceuticals. Genzyme Genetics was a leading provider of diagnostic testing and genetic counseling in the oncology and reproductive markets. Aspinall transformed the business from a small specialized player to one of the top five laboratories in the country while setting the industry standard for quality testing. The business was sold to LabCorp for nearly $1billion. Previously, she led Genzyme Pharmaceuticals and its transformation to an international leader in specialized pharmaceutical ingredient manufacturing.  A leader in educating payers and policymakers on personalized medicine, she served on the Health and Human Services Secretary’s Advisory Council on Genetics, Health & Society (SACGHS) in the Obama and Bush administrations. With a passion for education about the importance of diagnostics in healthcare, Aspinall co-founded the Biomedical Diagnostics program at Arizona State University, the first and only program dedicated to Diagnostics as an independent discipline. ASU awarded their first Master degrees in Diagnostics in 2015 and has 100 students matriculating this year.  Aspinall was named Arizona Biosciences Leader of the Year by the Arizona Biotechnology Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine and one of... Support this podcast

Mark Stinson has earned the reputation of a brand innovator – a strategist, creative facilitator, and venture catalyst.   His work has included branding, advertising, and marketing strategy for health, science, and technology products. Mark has worked with clients including: Global healthcare companies (Abbott, Baxter, DuPont, Merck KGaA, Pfizer, Takeda, UCB) Biotech leaders (Amgen, CSL Behring, Gilead, and Salix) Hospital products companies (Cardinal Health, Covidien, Fenwal, Hollister, Hospira) Drug delivery system developers (Adare, Endo, Kos) Medical start-ups (ClearCare, Magsense Nanoparticles, MedsForAll, Organ Recovery Systems, Plasticity Brain Centers, Solstice Neurosciences, Virgilant Technologies) Major university tech transfer (Boise State, Tulane, Purdue) ​ Mark is a frequent speaker and facilitator for sales meetings, advisory boards, and strategy workshops. He is the author of two business books, ForwardFast Branding and N-of-8 Groups, plus a contributor to 2 motivational books, Living in the Now and Alone In My Universe.   He is a recipient of the Brand Leadership Award from the Asia Brand Congress for global marketing efforts. He was included in the PharmaVoice 100 Most Inspiring People in the Life-Sciences Industry. Learn more about your ad choices. Visit https://megaphone.fm/adchoices (megaphone.fm/adchoices)

We launch our new series WWiSE with an empowering discussion with Dr. Joanne Kamens, the Executive Director of Addgene and the founder of the Massachusetts chapter of Association for Women in Science. She was recognized in the list of 2013 PharmaVOICE 100 Most Inspiring-Commanders & Chiefs and 2014 Forty Over 40 - Women Who are Making an Impact. She is passionate about gender equality, workplace inclusivity, and advocates for women and minorities in STEM fields. In this episode, Dr. Kamens gives us a snapshot of her journey in academia, pharma, and biotech, and let us question our prejudices, calls to act on them. She also gives us insights into Addgene’s efforts to build an equitable workplace environment!  “Inspired” by Kevin MacLeod is licensed under CC BY 4.0

TOPIC: The "New Normal" in Medical Media  LENGTH: 44:10PANELISTS: Eugene Lee and Jim Woodland, CMI/Compas; and Sima Sherman, Sherman Medical Marketing Group HOST: Jason E. CarrisSeason Two of the AMM Conversation, the official podcast of the Association of Medical Media, concludes with a final discussion of the "new normal" in medical media. In this episode, we are joined by a trio of medical media experts discussing how the industry is coping, adapting, and excelling during the Covid-19 pandemic.Our panelists today:Eugene Lee, Chief Operating Officer at CMI/Compas, where he is responsible for the global operations of media business leadership, media planning and media strategy disciplines across all clients. Eugene has been with CMI/Compas for over 25 years and is an AMM board member. Jim Woodland is CMI/Compas' Chief Strategy and Financial Officer. Jim has been the brains behind some of CMI/Compas’ most successful commercial and pricing models in the company’s 30-year history. He has been named to the PharmaVOICE 100 and is a 2020 Philadelphia Business Journal CFO of the year award honoree.Sima Sherman is founder and president of Sherman Medical Marketing Group. A full-service marketing and sales rep firm, Sima works with leading medical publishers and professional societies. She previously was VP of Sales and Marketing with American Medical Communications, and held similar roles with Triple Threat Media.Resources: Find additional medical media resources via AMM's Knowledge Exchange Center.Next: Be on the lookout for Season Three of the podcast this fall. The easiest way to know when the next season drops is to subscribe or follow the podcast.  Contact us:  AMM Conversation is the official podcast of the Association of Medical Media. Send questions and comments about this podcast series to jcarris525@gmail.com.

Marketer, brand innovator, and author Mark Stinson talks about the importance of branding whether it's for a multinational corporation, personal brand, or small business. Guest Biography Mark Stinson has earned the reputation as a “brand innovator” -- an experienced marketer, persuasive writer, dynamic presenter, and skilled facilitator. His work includes brand strategy and creative workshops. He has contributed to the launches of more than 150 brands, with a focus on health, science, and technology companies. Mark has worked with clients ranging from global corporations to entrepreneurial start-ups. He is a recipient of the Brand Leadership Award from the Asia Brand Congress and was included in the PharmaVoice 100 Most Inspiring People in the Life-Sciences Industry. Mark is the author of 5 business books and designer of many motivational journals. He is currently co-hosting a podcast entitled "Entelechy Leadership Stories." In this episode, you'll learn: The power of branding for big corporations, personal brand, or small business Mark's customer chemistry framework Responding to a crisis as a brand Show notes: http://www.inspiredmoney.fm/146 Find more from our guest: www.mark-stinson.com Amazon author page: Mark Stinson LinkedIn Books: ForwardFast Branding: The 6-Step Model to Accelerate Your Health, Science, and Technology Brand by Mark Stinson Customer CHEMistry: The 4 Elements to Create Lasting Relationships with Customers – and Lessons I Learned from Them by Mark Stinson Mentioned in this episode: www.ideo.com Runnymede Money Tip of the Week Buying generics and private label to save money. Thanks for Listening! To share your thoughts: Leave a note in the comment section below. Share this show on Twitter or Facebook. Join us at the Inspired Money Makers groups at facebook and LinkedIn To help out the show: Leave an honest review on Apple Podcasts, Podchaser.com, or wherever you listen. Your ratings and reviews really help, and I read each one. Email me your address, and I'll mail you an autographed copy of Kimo West and Ken Emerson's CD, Slackers in Paradise. Subscribe on Apple Podcasts. Special thanks to Jim Kimo West for the music.

Overview The Stevens Group has been presenting the PR Masters Series Podcast for almost two years now.  But never has a subject been explored as thoroughly as the role that the coronavirus plays in the present and future of public relations.  We've invited Gil Bashe back to steer us to our collective future as public relations professionals.  Gil's medical and healthcare background prepares him well to make observations that the rest of us haven't thought of.  You won't want to miss this special edition of PR Masters and learn from the consummate PR healthcare professional, Gil Bashe.  This series is part of the ongoing partnership between The Stevens Group and CommPRO to bring to PR, digital/interactive and marketing communications agencies the wisdom of those who have reached the top of the PR profession.   About Our Guest Gil Bashe, Managing Partner, Finn Partners Global Health Practice Champion for health innovation to sustain life and improve patient care, Gil has been tapped by PharmaVOICE “as one of the 100 most inspiring people in healthcare;” included in the Fast Company “50 People to Watch in the New World of Work”; chosen as a MM&M Top 10 Innovation Catalyst; by PRWeek/MM&M as a Top 50 Health Influencer;” recognized by the PRSA Health Academy with its “Excellence in Public Relations” award, and selected for the PRNews “Hall of Fame.” American Heart Association and Marfan Foundation advocate for patient engagement and access to care. Gil has led three top agencies cited by The Holmes Report as “Healthcare PR Agency of the Year” winners. Gil is associated with 40+ product launch campaigns for global med/tech and biopharma blockbusters in cancer, diabetes, heart, respiratory, women's health and non-communicable and orphan disease therapies. His background in payer, provider, policy, pharma marketing and patient-advocacy communications enables him to integrate ideas that impact patient access to care. He enables client messages and ideas to navigate successfully through the complex health ecosystem. Dedicated to inspiring colleagues to succeed for clients and their customers, he was Group Company CEO, CommonHealth, and at WPP Group sister-company Hill + Knowlton, EVP, Worldwide Health Practice Director – its first Global Practice Head. He served as CEO of Health!Quest Global Communication Partners, funded by GTCR Golder Rauner, a private-equity firm, now with $10 billion in active assets. Gil held leadership positions with New York agency Makovsky, Medicus, a global health-marketing company (today part of Publicis Healthcare), and at the pioneering integrated health-marketing agency Sutton Healthcare Group. As a health lobbyist, he was a director with the New Jersey Health Products Council.  He serves on the advisory boards of Lets Win for Pancreatic Cancer, Marfan Foundation and Galien Foundation.  He is also a member of the CNS Summit organizing committee and was honored by the Summit for his leadership role in the life science community. He completed his military service as a paratrooper combat medic and staff sergeant.@Gil_Bashe

In this episode, Brian Loew, founder and CEO of online patient portal Inspire, talks about the value to patients and caregivers of providing a safe and trustworthy online social network--a “peaceable kingdom,” as he calls it.Millions of patients representing 3,500 diseases--including many rare ones --come to Inspire.com for online community discussions focused on their own particular disease. The platform provides a place for meaningful conversations among patients and caregivers. It also allows them to share their insights in ways that advance clinical research. Patients want to support research, sometimes even initiating it themselves. And, more than ever, Loew says, researchers are interested in patient-reported information. If patients agree, they can also be connected to relevant clinical trials. Loew emphasizes that across all the conditions and forums, patients always have control over what data they share and where they share it--and in his experience, the more control they have, the more willing they are to share it. The recently added coronavirus section (www.inspire.com/coronavirus) also features video testimonials from patients with a variety of conditions describing why COVID-19 is disrupting their medical routines and threatening their health.Loew is a frequent speaker and writer on the topics of health-focused social networks and digital health. He sits on the boards of the Robert Packard Center for ALS Research at Johns Hopkins, and New Jersey Goals of Care. He was a “Red Jacket” recipient from PharmaVOICE magazine for his contributions to the industry.

In this episode, Brian Loew, founder and CEO of online patient portal Inspire, talks about the value to patients and caregivers of providing a safe and trustworthy online social network: a “peaceable kingdom,” as he calls it.Millions of patients representing 3,500 diseases—including many rare ones—come to Inspire.com for online community discussions focused on their own particular disease. The platform provides a place for meaningful conversations among patients and caregivers. It also allows them to share their insights in ways that advance clinical research. Patients want to support research, sometimes even initiating it themselves. And, more than ever, Loew says, researchers are interested in patient-reported information. If patients agree, they can also be connected to relevant clinical trials. Loew emphasizes that across all the conditions and forums, patients always have control over what data they share and where they share it—and in his experience, the more control they have, the more willing they are to share it. The recently added coronavirus section (Inspire.com/coronavirus) also features video testimonials from patients with a variety of conditions describing why COVID-19 is disrupting their medical routines and threatening their health.Loew is a frequent speaker and writer on the topics of health-focused social networks and digital health. He sits on the boards of the Robert Packard Center for ALS Research at Johns Hopkins, and New Jersey Goals of Care. He was a “Red Jacket” recipient from PharmaVOICE magazine for his contributions to the industry.

Overview The Stevens Group is pleased to present a new podcast series that salutes the masters of public relations and revels in their observations, insights and advice to PR professionals.  This new series is part of the ongoing partnership between The Stevens Group and CommPRO to bring to PR, digital/interactive and marketing communications agencies the wisdom of those who have reached the top of the PR profession.     About Our Guest Gil Bashe, Managing Partner, Finn Partners Global Health Practice Champion for health innovation to sustain life and improve patient care, Gil has been tapped by PharmaVOICE "as one of the 100 most inspiring people in healthcare;" included in the Fast Company “50 People to Watch in the New World of Work”; chosen as a MM&M Top 10 Innovation Catalyst; by PRWeek/MM&M as a Top 50 Health Influencer;" recognized by the PRSA Health Academy with its "Excellence in Public Relations" award, and selected for the PRNews "Hall of Fame." American Heart Association and Marfan Foundation advocate for patient engagement and access to care. Gil has led three top agencies cited by The Holmes Report as "Healthcare PR Agency of the Year" winners. Gil is associated with 40+ product launch campaigns for global med/tech and biopharma blockbusters in cancer, diabetes, heart, respiratory, women's health and non-communicable and orphan disease therapies. His background in payer, provider, policy, pharma marketing and patient-advocacy communications enables him to integrate ideas that impact patient access to care. He enables client messages and ideas to navigate successfully through the complex health ecosystem. Dedicated to inspiring colleagues to succeed for clients and their customers, he was Group Company CEO, CommonHealth, and at WPP Group sister-company Hill + Knowlton, EVP, Worldwide Health Practice Director - its first Global Practice Head. He served as CEO of Health!Quest Global Communication Partners, funded by GTCR Golder Rauner, a private-equity firm, now with $10 billion in active assets. Gil held leadership positions with New York agency Makovsky, Medicus, a global health-marketing company (today part of Publicis Healthcare), and at the pioneering integrated health-marketing agency Sutton Healthcare Group. As a health lobbyist, he was a director with the New Jersey Health Products Council.  He serves on the advisory boards of Lets Win for Pancreatic Cancer, Marfan Foundation and Galien Foundation.  He is also a member of the CNS Summit organizing committee and was honored by the Summit for his leadership role in the life science community. He completed his military service as a paratrooper combat medic and staff sergeant.

Our guest on this segment is 30-year veteran of the health and wellness communications industry. VINCE PARRY is the founder of the Parry Branding Group, and the author of Identity Crisis. In it he shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Vince was previously the Chief Branding Officer at inVentiv Health, the Founder and President of Y Brand, the Founder and President of GSW NY and the Chief Creative Officer at Sudler & Hennessey. He's appeared on NBC Nightly News with Brian Williams and BBC radio, has been featured in Medical Marketing and Media, PharmaVoice, Pharmaceutical Executive, and MedAdNews, and guest lectures at the Rutgers Pharmaceutical MBA program on healthcare branding. In his latest book, Identity Crisis, Parry shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Parry weaves examples from his work with industry leaders such as Merck, Bayer Healthcare, and Maimonides Medical Center, and reveals how differentiating healthcare brands have shaped our choices. By incorporating how we identify with illness and wellness into his innovative branding strategies, he has redefined how we make purchasing decisions to improve our lives and find relief. VINCE PARRY Parry Branding Group http://parrybrandinggroup.com/ (646) 850-4537 Learn more about your ad choices. Visit megaphone.fm/adchoices

Our guest on this segment is 30-year veteran of the health and wellness communications industry. VINCE PARRY is the founder of the Parry Branding Group, and the author of Identity Crisis. In it he shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Vince was previously the Chief Branding Officer at inVentiv Health, the Founder and President of Y Brand, the Founder and President of GSW NY and the Chief Creative Officer at Sudler & Hennessey. He's appeared on NBC Nightly News with Brian Williams and BBC radio, has been featured in Medical Marketing and Media, PharmaVoice, Pharmaceutical Executive, and MedAdNews, and guest lectures at the Rutgers Pharmaceutical MBA program on healthcare branding. In his latest book, Identity Crisis, Parry shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Parry weaves examples from his work with industry leaders such as Merck, Bayer Healthcare, and Maimonides Medical Center, and reveals how differentiating healthcare brands have shaped our choices. By incorporating how we identify with illness and wellness into his innovative branding strategies, he has redefined how we make purchasing decisions to improve our lives and find relief. VINCE PARRY Parry Branding Group http://parrybrandinggroup.com/ (646) 850-4537 Learn more about your ad choices. Visit megaphone.fm/adchoices